Clinical efficacy and safety of brinzolamide (azopt(TM)), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

American Journal of Ophthalmology

Volumn 126, Issue 3, 1998, Pages 400-408

  Silver, Lewis H ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; AGED; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SAFETY; SULFONAMIDES; THIAZINES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 0032169810     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00095-6     Document Type: Article

References (9)

1. Dean T., May J., Chen H.H., Kyba E., McLaughlin M., DeSantis L. Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey. ARVO abstracts. Invest Ophthalmol Vis Sci. 38:(4 suppl):1997;S813.
2. Wistrand P.J., Schenholm M., Lonnerhol G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthalmol Vis Sci. 27:1986;419-428.
3. Strahlman E., Tipping R., Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol. 122:1996;183-194.
4. Stewart R. The ocular comfort of TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension ARVO abstracts . Invest Ophthalmol Vis Sci. 38:(4 suppl):1997;S559.
5. Camras C.B. A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% and BID-dosed timolol 0.5% ARVO abstracts . Invest Ophthalmol Vis Sci. 38:(4 suppl):1997;S560.
6. Shin D.H. Adjunctive Study Group. A triple-masked, placebo-controlled, adjunctive study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5%. ARVO abstracts. Invest Ophthalmol Vis Sci. 38:(4 suppl):1997;S559.
7. Epstein D.L., Grant M. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol. 95:1977;1378-1382.
8. Lichter P.R., Newman L.P., Wheeler N.C., Beall O.V. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 85:1978;495-502.
9. Donohue E.K., Wilensky J.T. Trusopt, a topical carbonic anhydrase inhibitor. J Glaucoma. 5:1996;68-74.